Related Experiment Video
Updated: Nov 27, 2025

A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
Adequate anticoagulation and ECMO therapy in COVID-19 patients with severe pulmonary embolism
Christopher Gaisendrees1, Sebastian G Walter1, Ahmed Elderia1
1Department of Cardiothoracic Surgery, University Hospital of Cologne, Cologne, Germany.
Abstract:
SARS-CoV-2 (COVID-19) infections have been recently shown to be associated with a high rate of thromboembolic events due to pro-coagulative mechanisms that have not yet been fully understood. This paper reports on a 55-year-old female COVID-19 patient with severe ARDS and pulmonary embolism (PE) complicated by cardiogenic shock after 12 days of hospitalization under initial prophylactic anticoagulation with low molecular weight heparin (LMWH). An ultima-ratio va (veno-arterial) ECMO implantation and subsequent rapid upgrade to vvaECMO due to insufficient oxygenation was performed. The patient developed severe coagulopathy with intrapulmonary bleeding. The present report aims to highlight and discuss the pros and cons of various anticoagulation strategies in COVID-19 patients focusing on current scientific debates to address this frequently observed complication in the current situation worldwide.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
